Levsin Dose for Excess Secretions in Adults
For adults with excess secretions, administer Levsin (hyoscyamine sulfate) 1 to 2 tablets (0.125 mg each) every 4 hours as needed, not exceeding 12 tablets in 24 hours. 1
FDA-Approved Dosing
The FDA label for Levsin provides clear dosing parameters 1:
- Adults and patients ≥12 years: 1-2 tablets (0.125 mg) every 4 hours or as needed
- Maximum daily dose: 12 tablets (1.5 mg) in 24 hours
- Administration routes: Sublingual, oral, or chewed
The sublingual route may provide more rapid onset of action, though oral administration achieves the same pharmacological effects 1.
Pharmacological Rationale
Hyoscyamine sulfate is an anticholinergic agent that specifically inhibits acetylcholine at postganglionic cholinergic receptors 1. For secretion control, it works by blocking excessive pharyngeal, tracheal, and bronchial secretions while also inhibiting gastrointestinal propulsive motility and decreasing gastric acid secretion 1.
The drug is completely absorbed via both sublingual and oral routes, with a half-life of 2-3.5 hours 1. Most of the drug is excreted unchanged in urine within the first 12 hours.
Clinical Context from Related Guidelines
While the FDA label addresses general antisecretory use, guidelines for specific clinical scenarios provide additional context:
- For airway procedures: Hyoscine hydrobromide (a related compound) is dosed at 0.2-0.6 mg IM (administered 30-60 minutes pre-procedure) or 5-10 minutes IV, with longer-lasting systemic effects than other antisialogues 2
- For death rattle in palliative care: Hyoscine butylbromide 20 mg subcutaneous bolus followed by continuous infusion (60-120 mg/day) has demonstrated effectiveness 3, 4
Important Caveats
Dose titration is critical - start at the lower end of the dosing range (1 tablet every 4 hours) and adjust based on response and tolerability 1. Common side effects include dry mouth, tachycardia, dizziness, and potential sedation, particularly at higher doses.
Contraindications to consider: The drug crosses the blood-brain barrier and placental barrier 1, and should be used cautiously in patients with increased intraocular pressure (glaucoma), urinary retention, or cardiac conditions where tachycardia would be problematic.
The tablets can be administered via any of three routes (sublingual, oral, or chewed) based on patient preference and clinical situation, with sublingual potentially offering faster onset when rapid secretion control is needed 1.